Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918930 · ClinicalTrials.gov registry record · Phase 1
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
A Phase 1 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01918930 is a Phase 1 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 6 participants.
The verdict
NCT01918930, a Phase 1 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study. Patients with easily accessible tumors at the screening visit for participation in Study CP-MGA271-01 will be asked to participate in this substudy. Patients will undergo two excisional biopsies, punch biopsies, or core needle biopsies.
Interventions
- BIOLOGICAL MGA271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01918930
The ClinicalTrials.gov registry entry for NCT01918930 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGA271 is the first listed.
NCT01918930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01918930 about?
NCT01918930 is a clinical study titled "Tissue Procurement Substudy for Participants in Study CP-MGA271-01". The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study. Patients with easily accessible tumors at the screening visit for participation in Study CP-MGA271-01 will be asked to participate in this substudy. Patients w...
What is the current status of trial NCT01918930?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-07. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01918930?
The interventions under investigation include: MGA271 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01918930?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.